Our Focus

Cancer Lipid Metabolism


Cancer Molecular Therapies


image.png




Cancer Metabolism: Long History, Recent Breakthrough


image.png


image.png


image.png


image.png




Fatty Acid Synthase, A Promising Cancer Drug Target


image.png


image.png


image.png


image.png




Cancer Lipid Metabolism: Recent Breakthrough of FASN Inhibitors


• Investigator sponsored Phase 2 trial of TVB-2640 with Bevacizumab in Patients with First Relapse of High-Grade Astrocytoma 

       • 25 patients enrolled, both grade III and IV astrocytoma 

       • All patients received ASC40 (TVB-2640) (100mg/m2 PO QD) plus bevacizumab (10mg/kg IV D1,15) until treatment-related toxicity or progressive disease 

• The overall response rate (ORR) for ASC40 (TVB-2640) plus bevacizumab of 65% 

       • Complete response (CR) of 20% 

       • Partial response (PR) of 45% 

• Progression-free survival at six months (PFS6) for ASC40 (TVB-2640) plus bevacizumab was 47% 

       • Representing a statistically significant improvement in PFS6 over historical bevacizumab monotherapy (BELOB 16%, P=0.01) 

       • ASC40 (TVB-2640) in combination with bevacizumab was safe and well tolerated in such patient population 

• Presented at European Society for Medical Oncology 2020




Oral Checkpoint Inhibitors


PD-L1 Small Molecule Inhibitors: Challenges and Opportunities


image.png




ASC63: Induce PD-L1 Dimerization and Sustained Internalization


image.png